Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Profit After Tax (2021 - 2025)

Historic Profit After Tax for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $45.4 million.

  • SAB Biotherapeutics' Profit After Tax rose 53911.17% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 14112.53%. This contributed to the annual value of -$34.1 million for FY2024, which is 1916.98% up from last year.
  • SAB Biotherapeutics' Profit After Tax amounted to $45.4 million in Q3 2025, which was up 53911.17% from -$10.1 million recorded in Q2 2025.
  • SAB Biotherapeutics' Profit After Tax's 5-year high stood at $45.4 million during Q3 2025, with a 5-year trough of -$22.9 million in Q4 2023.
  • Its 5-year average for Profit After Tax is -$4.3 million, with a median of -$6.9 million in 2023.
  • As far as peak fluctuations go, SAB Biotherapeutics' Profit After Tax plummeted by 84592.72% in 2023, and later surged by 53911.17% in 2025.
  • SAB Biotherapeutics' Profit After Tax (Quarter) stood at -$11.6 million in 2021, then surged by 31.83% to -$7.9 million in 2022, then plummeted by 190.26% to -$22.9 million in 2023, then soared by 50.15% to -$11.4 million in 2024, then soared by 498.83% to $45.4 million in 2025.
  • Its last three reported values are $45.4 million in Q3 2025, -$10.1 million for Q2 2025, and -$5.2 million during Q1 2025.